Publications by authors named "Suzanna R Cowan"
Article Synopsis
- Fragment-based lead discovery was used to develop inhibitors for urokinase-type plasminogen activator (uPA), starting with the drug mexiletine (R)-5.
- Through structure-aided design, researchers created enhanced inhibitors that maintained crucial interactions while increasing potency by targeting additional areas of the active site.
- The final optimized compound, designated as 15, emerged as a strong, selective, and orally bioavailable uPA inhibitor.
